Analyst upgrades:

• Citigroup upgraded Phillips-Van Heusen (NYSE: PVH) to Buy from Hold following the company's Q1 results as it believes management is executing well in the current environment and that the company could meet the high end of guidance. The firm raised its price target to $24 from $19.
  
• Friedman Billings upgraded Cliffs Natural (NYSE: CLF) to Outperform from Market Perform as it believes capacity utilization has stabilized and CLF's valuation is attractive at current levels. The firm raised its price target to $27 from $23.
  
• Thomas Weisel believes demand at Microchip's industrial (NASDAQ: MCHP) customers has troughed and that market share loss concerns are unwarranted. The firm upgraded shares to Overweight from Market Weight and raised its target to $27 from $19.
• CBS Corp (NYSE: CBS) was upgraded to Neutral from Sell at Goldman.
  
• U-Store It Trust (NYSE: YSI) was raised to Outperform from Neutral at Baird.
  
• Ener1 (NASDAQ: HEV) was lifted at Banc of America/Merrill to Buy from Neutral.

Analyst upgrades:

• Goldman upgraded shares of British Sky Broadcasting (NYSE: BSY) to Buy from Neutral and added the company to the Conviction Buy List as they find the stock oversold at current levels.
  
• Goldman also added Publicis (OTC: PUBGY) to the Conviction Buy List and upgraded shares to Buy from Neutral as they find the stock cheap at current levels.
• Oneok (NYSE: OKE) was upgraded to Overweight from Equal Weight at Lehman.
  
• UBS raised Wimm-Bill-Dann Foods (NYSE: WBD) to Buy from Neutral.

Analyst downgrades:

• Baird downgraded Amylin Pharma (NASDAQ: AMLN) to Neutral from Outperform and said they are incrementally more cautious on the commercial performance of Amylin's Byetta following the yesterday's update. Amylin's target was lowered to $27 from $37. Soleil recommends investors avoid Amylin with the disclosure last night of four additional cases of mortality associated with pancreatitis in patients who were on Byetta. The firm cut shares to Sell from Hold and lowered their target to $20 from $25.
  
• Citigroup downgraded shares of AMR Corp. (NYSE: AMR) to Sell from Hold on valuation as they find the stock expensive following the recent run-up. The firm raised their target to $9 from $6.70 to reflect the drop in crude prices.
  
• J Crew (NYSE: JCG) was downgraded to Hold from Buy at Brean Murray following the weak Q2 report and guidance.
• JMP Securities downgraded Quality Systems (NASDAQ: QSII) to Market Perform from Outperform.
  
• National Grid (NYSE: NGG) was lowered to Equal Weight from Overweight at Lehman.

Analyst initiations:

MOST NOTEWORTHY: Cougar Biotech, Penford and AtriaCure were today's noteworthy initiations:

• Oppenheimer believes Cougar Biotech's (NASDAQ: CGRB) lead compound abiraterone is well positioned to address two underserved lines of therapy in prostate cancer with highly unmet medical needs. The firm assumed coverage of Cougar with a Buy rating and $43 target.
  
• Jefferies believes Penford's (NASDAQ: PENX) initiatives to improve product mix and increase returns on capital should lift the company's valuation multiples, starting shares with a Buy rating and $33 target.
  
• AtriaCure (NASDAQ: ATRC) was initiated with an Outperform rating and $17 target at Barrington, as they have confidence the company's minimally invasive approach will be the standard of care procedure for the less invasive surgical management of atrial fibrillation.

OTHER INITIATIONS:

• Penske Automotive (NYSE: PAG) was initiated with a Reduce rating and $17 target at Calyon.
  
• Broadpoint initiated Applied Material (NASDAQ: AMAT) with a Neutral rating.
  
• Jefferies initiated eHealth (NASDAQ: EHTH) with a Buy rating and $36 target.